A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 756 participants.

Also called NCT07915609

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 756 participants (planned count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07915609
  • EU CT 2026-527180-15-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07915609. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-26 (actual); primary completion 2028-08-21 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Condition
Obesity
Condition
Overweight and/or Obesity
Condition
Knee Osteoarthritis
Condition
Diabetes Melliuts, Type 2
Intervention (Drug)
Berobenatide
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct07915609
Content hash
e5552cb957a2d54bb08f437f06dc0a880c339fda706998c6fae5386ecb156609